Li Zhiming, Sun Jihong, Chen Lumin, Huang Ning, Hu Peng, Hu Xi, Han Guocan, Zhou Yurong, Bai Weixian, Niu Tianye, Yang Xiaoming
Department of Radiology, Sir Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Life Science, GE Healthcare China, Beijing, China.
J Magn Reson Imaging. 2016 Jul;44(1):98-104. doi: 10.1002/jmri.25132. Epub 2015 Dec 28.
To evaluate the pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in diagnosing and staging liver fibrosis in rabbits.
DCE-MRI with gadodiamide (Gd-DTPA-BMA) was performed on a 3.0 Tesla, 60 cm bore MR scanner for rabbits with CCl4 -induced liver fibrosis, and an untreated control group. Fibrosis was staged according to the METAVIR system: control (F0; n = 13), nonadvanced fibrosis (F1-2; n = 15), and advanced fibrosis (F3-4; n = 12). The DCE-MRI parameters K(trans) , kep , Ve , and vp were measured with a dual-input extended Tofts model. Receiver operating characteristic analyses were performed to assess the diagnostic performance of K(trans) , Ve , and vp in staging liver fibrosis.
Both K(trans) and Ve decreased with increasing fibrosis stage. K(trans) of the control group was significantly different from that of the overall fibrosis group, nonadvanced group, and advanced group (P < 0.001 for all). Significant differences were found between Ve of the control group and that of the overall fibrosis and advanced groups (P = 0.019 and P = 0.009, respectively). For K(trans) , the areas under the receiver operating characteristic curve (AUROCs) for discriminating the control group from the overall fibrosis and advanced fibrosis groups were 0.909 (95% confidence interval [CI], 0.809-1.000), and 0.936 (95% CI,0.847-1.000), respectively. For discriminating between the control and nonadvanced fibrosis groups, the AUROC of K(trans) was 0.887 (95% CI, 0.762-1.000). The AUROCs of K(trans) were higher than those of Ve and vp for discriminating between the control and overall fibrosis groups, the control and nonadvanced fibrosis groups, and the control and advanced fibrosis groups. Pharmacokinetic parameters were negatively correlated with fibrosis stage (K(trans) , rho = -0.668, P < 0.001; Ve , rho = -0.438, P = 0.005; vp , rho = -0.360, P = 0.023).
Among pharmacokinetic parameters of DCE-MRI in our study, K(trans) was an excellent predictor for differentiating fibrotic livers from normal livers, and differentiating normal livers from nonadvanced or advanced fibrosis livers. J. Magn. Reson. Imaging 2016;44:98-104.
评估动态对比增强磁共振成像(DCE-MRI)在兔肝纤维化诊断及分期中的药代动力学参数。
使用钆双胺(Gd-DTPA-BMA)对四氯化碳诱导的兔肝纤维化模型及未处理的对照组进行3.0特斯拉、60厘米孔径的磁共振成像扫描。根据METAVIR系统对纤维化进行分期:对照组(F0;n = 13)、非进展期纤维化组(F1-2;n = 15)和进展期纤维化组(F3-4;n = 12)。采用双输入扩展Tofts模型测量DCE-MRI参数K(trans)、kep、Ve和vp。进行受试者操作特征分析以评估K(trans)、Ve和vp在肝纤维化分期中的诊断性能。
K(trans)和Ve均随纤维化分期增加而降低。对照组的K(trans)与总体纤维化组、非进展期组和进展期组均有显著差异(均P < 0.001)。对照组的Ve与总体纤维化组和进展期组有显著差异(分别为P = 0.019和P = 0.009)。对于K(trans),区分对照组与总体纤维化组和进展期纤维化组的受试者操作特征曲线下面积(AUROC)分别为0.909(95%置信区间[CI],0.809 - 1.000)和0.936(95% CI,0.847 - 1.000)。区分对照组与非进展期纤维化组时,K(trans)的AUROC为0.887(95% CI,0.762 - 1.000)。在区分对照组与总体纤维化组、对照组与非进展期纤维化组以及对照组与进展期纤维化组时,K(trans)的AUROC高于Ve和vp。药代动力学参数与纤维化分期呈负相关(K(trans),rho = -0.668,P < 0.001;Ve,rho = -0.438,P = 0.005;vp,rho = -0.360,P = 0.023)。
在本研究的DCE-MRI药代动力学参数中,K(trans)是区分纤维化肝脏与正常肝脏、区分正常肝脏与非进展期或进展期纤维化肝脏的优秀预测指标。《磁共振成像杂志》2016年;44:第98 - 104页 。